Form 4: Pyxis Oncology Director Jakob Dupont Acquires Stock Options

Director Jakob Dupont acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Summary

• On March 31, 2025, Jakob Dupont, a director of Pyxis Oncology, Inc., acquired stock options.
• The options grant him the right to buy 36,979 shares of common stock at an exercise price of $0.98 per share.
• The options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• Following the transaction, Dupont directly owns 36,979 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather a routine part of executive compensation.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biotechnology industry where stock options are frequently used as part of compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence, as it signals a director's belief in the company's future.

Key Dates

Keywords

stock options, director, Jakob Dupont, Pyxis Oncology, PYXS, beneficial ownership, Form 4, securities